Here are three things to know.
1. According to Additive Orthopaedics’ vice president of engineering and operations Brian McLaughlin, the lattice structures have shown close to 90 percent bony in-growth after six months using no biologics.
2. Since its commercial launch in 2017, there have been more than 1,000 implantations of Additive Orthopaedics’ devices.
3. The company recently closed a series B funding round of $1 million.
More articles on surface technology:
4 things to know about the U.S. launch of K2M’s Mojave PL 3D Expandable Interbody System
3 things to know about Tiger Shark, ChoiceSpine’s new porous titanium interbody device
‘Nanotechnology is the way of the future’: Dr. David DeWitt on spinal implant nanosurface technology
